Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

John Carroll

Editor & Founder

Just a few weeks after offering a positive readout on its first early clinical-stage offering, the transatlantic biotech Immatics is back with news that …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

John Carroll

Editor & Founder

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Bris­tol My­ers antes up on a $920M part­ner­ship play for a next-gen — but ear­ly stage — bis­pe­cif­ic with a cou­ple of unique twists

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Bristol Myers antes up on a $920M partnership play for a next-gen — but early stage — bispecific with a couple of unique twists

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Applied Therapeutics' rare disease drug gets a CRL

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya